• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Public Health >Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?
【24h】

Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?

机译：Covid-19大流行期间癌症护理的医疗责任：英雄或内疚？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The COVID-19 outbreak rapidly became a public health emergency affecting particularly the frail category as cancer patients. This led oncologists to radical changes in patient management, facing the unprecedent issue whether treatments in oncology could be postponed without compromising their efficacy. Purpose: To discuss legal implications in oncology practice during the COVID-19 pandemic. Perspective: Treatment delay is not always feasible in oncology where the timing often plays a key role and may impact significantly in prognosis. During the COVID-19 pandemic, the oncologists were found between the anvil and the hammer, on the one hand the need to treat cancer patients aiming to improve clinical benefits, and on the other hand the goal to reduce the risk of COVID-19 infection avoiding or delaying immunosuppressive treatments and hospital exposure. Therefore, two rising scenarios with possible implications in both criminal and civil law are emerging. Firstly, oncologists may be “accused” of having delayed or omitted the diagnosis and/or treatments with consequent worsening of patients' outcome. Secondly, oncologists can be blamed for having exposed patients to hospital environment considered at risk for COVID-19 transmission. Conclusions: During the COVID-19 pandemic, clinical decision making should be well-balanced through a careful examination between clinical performance status, age, comorbidities, aim of the treatment, and the potential risk of COVID-19 infection in order to avoid the risk of suboptimal cancer care with potential legal repercussion. Moreover, all cases should be discussed in the oncology team or in the tumor board in order to share the best strategy to adopt case by case.
机译：背景：Covid-19爆发迅速成为患有癌症患者的公共卫生紧急情况。这一LED诱发学家对患者管理的激进变化，面临前所未有的问题，无论肿瘤学治疗是否可以推迟，而不会影响其疗效。目的：在Covid-19流行期间讨论肿瘤学实践中的法律影响。透视：治疗延迟在肿瘤中并不可行，在肿瘤学中，时间经常发挥关键作用，可能会在预后显着影响。在Covid-19大流行期间，鼻科医生在铁砧和锤子之间发现，一方面需要治疗癌症患者，旨在提高临床效益，另一方面是降低Covid-19感染风险的目标避免或延迟免疫抑制治疗和医院接触。因此，出现了两个在刑事和民法中可能影响的两种情况。首先，肿瘤科医师可以“被告”延迟或省略诊断和/或治疗，从而使患者的结果恶化。其次，可以将肿瘤科医师归咎于将患者暴露于患者对Covid-19传输风险的医院环境。结论：在Covid-19流行病中，临床决策应通过仔细检查临床表现状态，年龄，合并症，治疗目的之间的仔细检查，以及Covid-19感染的潜在风险，以避免风险次优癌症关怀潜在法律反应。此外，所有案例都应在肿瘤学团队或肿瘤委员会中讨论，以便以案例分享采用案件的最佳策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号